Blase N Polite
Overview
Explore the profile of Blase N Polite including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
2239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Snyder R, He J, Le-Rademacher J, Ou F, Dodge A, Zemla T, et al.
Cancer
. 2021 Aug;
127(20):3801-3808.
PMID: 34374082
Background: The objective of this study was to evaluate the association between self-identified race and overall survival (OS), progression-free survival (PFS), and response to therapy among patients enrolled in the...
12.
Foster C, Fleming G, Karrison T, Liao C, Desai A, Moroney J, et al.
Clin Cancer Res
. 2021 Jun;
27(20):5510-5518.
PMID: 34168049
Purpose: CD137 agonism and CSF1R blockade augment stereotactic body radiotherapy (SBRT) and anti-programmed death-1 in preclinical models. We evaluated the safety and efficacy of SBRT with nivolumab+urelumab (CD137 agonist) or...
13.
Jones L, Brewer K, Carnahan L, Parsons J, Polite B, Estwing Ferrans C, et al.
Public Health Rep
. 2021 Apr;
137(3):479-487.
PMID: 33789522
Objective: For colon cancer patients, one goal of health insurance is to improve access to screening that leads to early detection, early-stage diagnosis, and polyp removal, all of which results...
14.
Dreyer T, Wilfong L, Patel K, Gamble B, Polite B
JCO Oncol Pract
. 2021 Feb;
17(4):173-176.
PMID: 33539172
No abstract available.
15.
Guercio B, Zhang S, Ou F, Venook A, Niedzwiecki D, Lenz H, et al.
JNCI Cancer Spectr
. 2021 Jan;
5(1).
PMID: 33426464
Background: Energy balance-related biomarkers are associated with risk and prognosis of various malignancies. Their relationship to survival in metastatic colorectal cancer (mCRC) requires further study. Methods: Baseline plasma insulin-like growth...
16.
Berger Y, Giurcanu M, Vining C, Schuitevoerder D, Posner M, Roggin K, et al.
Ann Surg Oncol
. 2021 Jan;
28(8):4433-4443.
PMID: 33420565
Background: The authors hypothesized that cytoreductive surgery (CRS, comprising gastrectomy combined with metastasectomy) in addition to systemic chemotherapy (SC) is associated with a better survival than chemotherapy alone for patients...
17.
Catenacci D, Moya S, Lomnicki S, Chase L, Peterson B, Reizine N, et al.
Cancer Discov
. 2020 Nov;
11(2):308-325.
PMID: 33234578
The one-year and median overall survival (mOS) rates of advanced gastroesophageal adenocarcinomas (GEA) are ∼50% and <12 months, respectively. Baseline spatial and temporal molecular heterogeneity of targetable alterations may be...
18.
Guercio B, Zhang S, Venook A, Ou F, Niedzwiecki D, Lenz H, et al.
JNCI Cancer Spectr
. 2020 Nov;
4(3):pkaa024.
PMID: 33134818
Background: In nonmetastatic colorectal cancer, overweight and mild-to-moderately obese patients experience improved outcomes compared with other patients. Obesity's influence on advanced or metastatic colorectal cancer (mCRC) is relatively unexplored. Methods:...
19.
Van Blarigan E, Zhang S, Ou F, Venlo A, Ng K, Atreya C, et al.
JAMA Netw Open
. 2020 Oct;
3(10):e2023500.
PMID: 33125497
Importance: Diet has been associated with survival in patients with stage I to III colorectal cancer, but data on patients with metastatic colorectal cancer are limited. Objective: To examine the...
20.
Polite B, Ratain M, Lichter A
JAMA Oncol
. 2020 Oct;
7(1):25-26.
PMID: 33001134
No abstract available.